Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01FA10 AZITHROMYCINUM PULB. PT. SUSP. ORALĂ 100 mg/5ml
AZITROMICINA SANDOZ 100 mg/5ml SANDOZ SRL
100 mg/5ml
J01FA10 AZITHROMYCINUM COMPR. FILM. 125 mg
SUMAMED 125 mg 125 mg PLIVA LJUBLJANA D.O.O.
J01FA10 AZITHROMYCINUM PULB. PT. SUSP. ORALĂ 200 mg/5 ml
AZITROMICINA SANDOZ 200 mg/5 ml SANDOZ SRL
200 mg/5 ml
J01FA10 AZITHROMYCINUM PULB. + SOLV. 200 mg/5ml
SUSP. ORALĂ
AZITROX 200 mg/5 ml 200 mg/5 ml ECZACIBASI PHARMACEUTICALS
S.R.L.
J01FA10 AZITHROMYCINUM PULB. PT. SUSP. ORALĂ 200 mg/5ml
SUMAMED FORTE 200 mg/5ml PLIVA LJUBLIJANA D.O.O.
J01FA10 AZITHROMYCINUM CAPS. 250 mg
AZATRIL 250 mg 250 mg BALKANPHARMA RAZGRAD AD
J01FA10 AZITHROMYCINUM COMPR. FILM. 250 mg
AZITROMICINA SANDOZ 250 mg 250 mg SANDOZ S.R.L.
COMPRIMATE FILMATE
AZITROX(R) 250 250 mg ZENTIVA AS
J01FA10 AZITHROMYCINUM LIOF. PT. SOL. PERF. 500 mg
SUMAMED(R) 500 mg PLIVA LJUBLJANA D.O.O.
J01FA10 AZITHROMYCINUM COMPR. FILM. 500 mg
AZITROMICINA SANDOZ 500 mg 500 mg SANDOZ S.R.L.
COMPRIMATE FILMATE
AZITROX(R) 500 500 mg ZENTIVA AS
AZRO(R) 500 mg 500 mg ECZACIBASI PHARMACEUTICALS
S.R.L.
SUMAMED 500 mg 500 mg PLIVA LJUBLJANA D.O.O.
ZITROCIN 500 mg 500 mg OZONE LABORATORIES LTD.
J01FA10 AZITHROMYCINUM GRAN. ELIB. PREL PT. 2 g
SUSP. ORALĂ
ZMAX 2 g 2 g PFIZER EUROPE MA EEIG
________________________________________________________________________________
______________________________________________________________________________
| 580 |J01MA02| CIPROFLOXACINUM | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Gonoreea.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J01MA02 CIPROFLOXACINUM COMPR. FILM. 250 mg
CIFRAN 250 mg RANBAXY UK LIMITED
CIPHIN 250 250 mg ZENTIVA A.S.
CIPRINOL 250 mg 250 mg KRKA D.D. NOVO MESTO
CIPROCIN 250 mg 250 mg E.I.P.I.CO. MED S.R.L.
CIPROFLOXACINA ALKALOID 250 mg ALKALOID D.O.O.
250 mg
CIPROLEN(R) 250 mg 250 mg AC HELCOR SRL
CIPROLET 250 mg 250 mg DR. REDDY'S LABORATORIES
CIPROZONE 250 mg 250 mg OZONE LABORATORIES LTD.
CUMINOL 250 mg 250 mg GEDEON RICHTER ROMANIA
J01MA02 CIPROFLOXACINUM CONC. PT. SOL. PERF. 100 mg/10 ml
CIPRINOL(R) 100 mg/10 ml KRKA D.D.
CIPROFLOXACINA 100 mg/10 ml 100 mg/10 ml SICOMED SA
J01MA02 CIPROFLOXACINUM SOL. PERF. 100 mg/50 ml
CIPRINOL 100 mg/50 ml KRKA D.D. NOVO MESTO
J01MA02 CIPROFLOXACINUM SOL. PERF. 200 mg/100 ml
CIPRINOL 200 mg/100 ml KRKA D.D. NOVO MESTO
CIPROBAY(R) 200 200 mg/100 ml BAYER HEALTHCARE AG
J01MA02 CIPROFLOXACINUM CAPS. 250 mg
EUCIPRIN 250 mg EUROPHARM SA
J01MA02 CIPROFLOXACINUM COMPR. FILM. 250 mg
CIFRAN 250 mg RANBAXY UK LIMITED
CIPHIN 250 250 mg ZENTIVA A.S.
CIPRINOL 250 mg 250 mg KRKA D.D. NOVO MESTO
CIPROCIN 250 mg 250 mg E.I.P.I.CO. MED S.R.L.
CIPROFLOXACINA ALKALOID 250 mg ALKALOID D.O.O.
250 mg
CIPROLEN(R) 250 mg 250 mg AC HELCOR SRL
CIPROLET 250 mg 250 mg DR. REDDY'S LABORATORIES
CIPROZONE 250 mg 250 mg OZONE LABORATORIES LTD.
CUMINOL 250 mg 250 mg GEDEON RICHTER ROMANIA
J01MA02 CIPROFLOXACINUM SOL. PERF. 2 mg/ml
CIPROBAY(R) 400 2 mg/ml BAYER HEALTHCARE AG
UFEXIL 2 mg/ml DEMO SA
J01MA02 CIPROFLOXACINUM SOL. PERF. 400 mg/200 ml
CIPRINOL(R) 400 mg/200 ml KRKA D.D.
J01MA02 CIPROFLOXACINUM COMPR. FILM. 500 mg
CIFRAN 500 mg RANBAXY UK LIMITED
CIPHIN 500 500 mg ZENTIVA A.S.
CIPRINOL 500 mg 500 mg KRKA D.D. NOVO MESTO
CIPRO QUIN(R) 500 mg ANTIBIOTICE SA
CIPROBAY(R) 500 500 mg BAYER HEALTHCARE AG
CIPROCIN 500 mg 500 mg E.I.P.I.CO. MED S.R.L.
CIPRODAR 500 mg DAR AL DAWA PHARMA S.R.L
CIPROFLOXACINA ALKALOID 500 mg ALKALOID D.O.O.
500 mg
CIPROLEN(R) 500 mg 500 mg AC HELCOR SRL
CIPROLET 500 mg 500 mg DR. REDDY'S LABORATORIES
CIPROZONE FORTE 500 mg 500 mg OZONE LABORATORIES LTD.
CUMINOL 500 mg 500 mg GEDEON RICHTER ROMANIA
SIFLOKS(R) 500 mg ECZACIBASI ILAC SANAYI VE
TICARET AS
J01MA02 CIPROFLOXACINUM COMPR. FILM. 750 mg
CIPRINOL 750 mg 750 mg KRKA D.D. NOVOMESTO
________________________________________________________________________________
SUBLISTA C1 - G31A BOALĂ CRONICĂ INFLAMATORIE INTESTINALĂ.
Protocol: L034K
______________________________________________________________________________
| 582 |L04AA12| INFLIXIMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA12 INFLIXIMABUM PULB. PT. CONC. PT. 100 mg
SOL. PERF.
REMICADE 100 mg 100 mg CENTOCOR B.V.
________________________________________________________________________________
______________________________________________________________________________
| 583 |L04AA17| ADALIMUMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA17 ADALIMUMABUM SOL. INJ. ÎN SERINGĂ 40 mg
PREUMPLUTĂ
HUMIRA 40 mg 40 mg ABBOTT LABORATORIES LTD.
________________________________________________________________________________
SUBLISTA C1 - G31B POLIARTRITĂ REUMATOIDĂ.
Protocol: L043M
______________________________________________________________________________
| 584 |L01XC02| RITUXIMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L01XC02 RITUXIMABUM CONC. PT. SOL. PERF. 10 mg/ml
MABTHERA 100 mg 10 mg/ml ROCHE REGISTRATION LTD.
MABTHERA 500 mg 10 mg/ml ROCHE REGISTRATION LTD.
________________________________________________________________________________
______________________________________________________________________________
| 585 |L04AA11| ETANERCEPTUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 25 mg
PREUMPLUTĂ
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 50 mg
PREUMPLUTĂ
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
________________________________________________________________________________
______________________________________________________________________________
| 586 |L04AA12| INFLIXIMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA12 INFLIXIMABUM PULB. PT. CONC. 100 mg
PT. SOL. PERF.
REMICADE 100 mg 100 mg CENTOCOR B.V.
________________________________________________________________________________
______________________________________________________________________________
| 587 |L04AA17| ADALIMUMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA17 ADALIMUMABUM SOL. INJ. ÎN SERINGĂ 40 mg
PREUMPLUTĂ
HUMIRA 40 mg 40 mg ABBOTT LABORATORIES LTD.
SUBLISTA C1 - G31C ARTROPATIA PSORIAZICA.
Protocol: L040M
______________________________________________________________________________
| 589 |L04AA11| ETANERCEPTUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 25 mg
PREUMPLUTĂ
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 50 mg
PREUMPLUTĂ
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
________________________________________________________________________________
______________________________________________________________________________
| 590 |L04AA12| INFLIXIMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA12 INFLIXIMABUM PULB. PT. CONC. PT. 100 mg
SOL. PERF.
REMICADE 100 mg 100 mg CENTOCOR B.V.
________________________________________________________________________________
______________________________________________________________________________
| 591 |L04AA17| ADALIMUMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA17 ADALIMUMABUM SOL. INJ. ÎN SERINGĂ 40 mg
PREUMPLUTĂ
HUMIRA 40 mg 40 mg ABBOTT LABORATORIES LTD.
________________________________________________________________________________
SUBLISTA C1 - G31D SPONDILITA ANKILOZANTA.
Protocol: L041M
______________________________________________________________________________
| 592 |L04AA11| ETANERCEPTUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 25 mg
PREUMPLUTĂ
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 50 mg
PREUMPLUTĂ
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
________________________________________________________________________________
______________________________________________________________________________
| 593 |L04AA12| INFLIXIMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA12 INFLIXIMABUM PULB. PT. CONC. PT. 100 mg
SOL. PERF.
REMICADE 100 mg 100 mg CENTOCOR B.V.
________________________________________________________________________________
______________________________________________________________________________
| 594 |L04AA17| ADALIMUMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA17 ADALIMUMABUM SOL. INJ. ÎN SERINGĂ 40 mg
PREUMPLUTĂ
HUMIRA 40 mg 40 mg ABBOTT LABORATORIES LTD.
________________________________________________________________________________
SUBLISTA C1 - G31E ARTRITA JUVENILA.
Protocol: L039M
______________________________________________________________________________
| 595 |L04AA11| ETANERCEPTUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT.
SOL. INJ. 50 mg
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB. + SOLV. PT. 25 mg
SOL. INJ.
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT. 50 mg
SOL. INJ.
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 25 mg
PREUMPLUTĂ
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 50 mg
PREUMPLUTĂ
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
________________________________________________________________________________
SUBLISTA C1 - G31F PSORIAZIS CRONIC SEVER (PLACI).
Protocol: L044L
______________________________________________________________________________
| 596 |L04AA11| ETANERCEPTUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA11 ETANERCEPTUM PULB. + SOLV. PT.
SOL. INJ. 25 mg
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT.
SOL. INJ. 50 mg
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB. + SOLV. PT.
SOL. INJ. 25 mg
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM PULB + SOLV. PT.
SOL. INJ. 50 mg
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ
PREUMPLUTĂ 25 mg
ENBREL 25 mg 25 mg WYETH EUROPA LIMITED
L04AA11 ETANERCEPTUM SOL. INJ. ÎN SERINGĂ 50 mg
PREUMPLUTĂ
ENBREL 50 mg 50 mg WYETH EUROPA LIMITED
________________________________________________________________________________
______________________________________________________________________________
| 597 |L04AA12| INFLIXIMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA12 INFLIXIMABUM PULB. PT. CONC. PT. 100 mg
SOL. PERF.
REMICADE 100 mg 100 mg CENTOCOR B.V.
________________________________________________________________________________
______________________________________________________________________________
| 598 |L04AA21| EFALIZUMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA21 EFALIZUMABUM PULB + SOLV. PT.
SOL. INJ. 100 mg/ml
RAPTIVA 100 mg/ml 100 mg/ml SERONO EUROPE LTD.
________________________________________________________________________________
______________________________________________________________________________
| 599 |L04AA17| ADALIMUMABUM**** | |
|_______|_______|____________________________________________|_________________|
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
L04AA17 ADALIMUMABUM SOL. INJ. ÎN SERINGĂ 40 mg
PREUMPLUTĂ
HUMIRA 40 mg 40 mg ABBOTT LABORATORIES LTD.
________________________________________________________________________________
SUBLISTA C2 - P1: PROGRAMUL NAŢIONAL DE BOLI TRANSMISIBILE. A) SUBPROGRAMUL DE TRATAMENT ŞI MONITORIZARE A PERSOANELOR CU INFECŢIE HIV/SIDA ŞI TRATAMENTUL POSTEXPUNERE
______________________________________________________________________________
| 600 |J05AE01| SAQUINAVIRUM | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul infecţiei HIV la pacienţii cu: celule CD4 < 500 pe mm cub sau încărcare virală > 10.000 copii per ml.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J05AE01 SAQUINAVIRUM CAPS. 200 mg
INVIRASE 200 mg 200 mg ROCHE REGISTRATION LTD.
J05AE01 SAQUINAVIRUM COMPR. FILM. 500 mg
INVIRASE 500 mg 500 mg ROCHE REGISTRATION LTD.
________________________________________________________________________________
______________________________________________________________________________
| 601 |J05AE02| INDINAVIRUM | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul infecţiei HIV la pacienţii cu: celule CD4 < 500 pe mm cub sau încărcare virală > 10.000 copii per ml.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________
DCI/DENUMIRE COMERCIALĂ FORMA FARM.
__________________________________________________
CONCENTRAŢIE FIRMA
________________________________________________________________________________
J05AE02 INDINAVIRUM CAPS. 200 mg
CRIXIVAN 200 mg 200 mg MERCK SHARP & DOHME LTD.
J05AE02 INDINAVIRUM CAPS. 400 mg
CRIXIVAN 400 mg 400 mg MERCK SHARP & DOHME LTD.
________________________________________________________________________________
______________________________________________________________________________
| 602 |J05AE03| RITONAVIRUM** | |
|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul infecţiei HIV la pacienţii cu: celule CD4 < 500 pe mm cub sau încărcare virală > 10.000 copii per ml.
Dostları ilə paylaş: |